This Article Reprint (PDF) Submit a response to this article Alert me when this article is cited Alert me when Comments are posted Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to Citation Manager Reprints & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (3) Citing Articles via Google Scholar Google Scholar Articles by Moran, D. W. Search for Related Content PubMed PubMed Citation Articles by Moran, D. W. Related Collections Managed Care Pharmaceuticals

Health Affairs, Vol 19, Issue 2, 63-77
Copyright © 2000 by Project HOPE

Journal Article

Prescription drugs and managed care: can 'free-market detente' hold?

The rapid rise in pharmaceutical benefits costs, often cited as a major contributor to the resurgence in health care cost growth, is beginning to strain the relationship between the pharmaceutical and the managed care industries in the United States. In interviews conducted in 1999, executives from both industries maintained a continued preference for a market-based resolution of these tensions. There is evidence, however, that this private-sector detente may give way in the face of the rising business and political pressures that both industries face. Active leadership will be required to prevent deterioration of the prevailing political climate toward economic controls.

                      What's this?

This article has been cited by other articles:

				J. Kennedy and C. Erb Prescription Noncompliance due to Cost Among Adults With Disabilities in the United States Am J Public Health, July 1, 2002; 92(7): 1120 - 1124. [Abstract] [Full Text] [PDF]